The COMB group showed significant increases in the tumor accumulation of 111In-DOTA-anti-OX40 mAb compared to the CUR and RT groups, indicating that the combination treatment may elicit a more robust anti-tumor immune response. Here, TNFRSF4 is linked to neoplasm.